Patents Assigned to PTC
  • METHODS FOR TREATING EPILEPSY
    Publication number: 20200188362
    Abstract: Provided herein are methods of treating, preventing, ameliorating or managing a nonsense mutation mediated epileptic disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nonsense mutation mediated epileptic disease. In particular, provided herein are methods of treating, preventing, ameliorating or managing a CDKL5 and/or SCN1A (Dravet syndrome) nonsense mutation mediated epileptic disease.
    Type: Application
    Filed: November 7, 2019
    Publication date: June 18, 2020
    Applicant: PTC Therapeutics, Inc.
    Inventors: Ellen Welch, Yuki Tomizawa, Priya Vazirani
  • Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease
    Patent number: 10675272
    Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: June 9, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventors: Samit Hirawat, Langdon Miller
  • Methods for modulating RNA splicing
    Patent number: 10668171
    Abstract: In one aspect, described herein is a recognition element for splicing modifier (REMS) that can be recognized by a compound provided herein. In another aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains a REMS, and the methods utilizing a compound described herein. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product encoded by a gene, wherein a precursor RNA transcript transcribed from the gene comprises a REMS, and the methods utilizing a compound described herein. In another aspect, provided herein are artificial gene constructs comprising a REMS, and uses of those artificial gene constructs to modulate functional protein production.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 2, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventors: Nikolai Naryshkin, Amal Dakka
  • Adaptor for ornamental light emitting device and candolier including the same
    Patent number: 10665997
    Abstract: An adaptor to drive DC powered light emitting device from an AC power source includes a main body having a first coupler configured to be connected to an external AC socket, a printed circuit board (PCB) disposed in the main body, an auxiliary body having a second coupler configured to be connected to the DC powered light emitting device, and a flexible, adjustable length connector extending outwardly from the main body between the PCB and the second coupler.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: May 26, 2020
    Assignee: PTC International, Inc.
    Inventors: Michael Sangyup Lee, Gianni Andracchio, Kurt Ciliberto
  • Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
    Patent number: 10618877
    Abstract: Provided herein are pharmaceutical compositions, which comprise a 1,2,4-oxadiazole benzoic acid or a pharmaceutically acceptable salt thereof. Further provided herein are certain pharmaceutically acceptable salts of a 1,2,4-oxadiazole benzoic acid and methods for making the same. Further provided herein are methods of treating or preventing a disease associated with a nonsense mutation or a premature stop codon, comprising administering such pharmaceutical compositions or pharmaceutically acceptable salts to a patient having a disease associated with a nonsense mutation or a premature stop codon.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: April 14, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventors: Marla L. Weetall, Ellen Welch, Mandar V. Dali, James Takasugi
  • CAD-based design control
    Patent number: 10591898
    Abstract: Exemplary embodiments relate to methods, mediums, and systems for associating information, including critical-to-quality (CTQ) information such as minimum or maximum part dimensions, with parts in a three-dimensional model of a product. The information may be identified by performing a failure mode effect analysis (FMEA) against the model. The information is stored with the model data (e.g., in the form of an annotation applied to a model feature corresponding to the part in question). The model data may be consulted by product lifecycle management (PLM) applications during various phases of the product's lifecycle. Among other possibilities, the information may be used to automatically generate regulatory compliance documentation, to ensure product quality standards are met during a manufacturing process, or to perform postproduction quality monitoring of the product.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 17, 2020
    Assignee: PTC, Inc
    Inventors: David Wolf, Michael Prudhomme, Swapan Jha, Jeff Milkey
  • Substituted pyridine and pyrazine BMI-1 inhibitors
    Patent number: 10584115
    Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 10, 2020
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Ramil Baiazitov, Soongyu Choi, Wu Du, Seongwoo Hwang, Chang-Sun Lee, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Scripting web services
    Patent number: 10574790
    Abstract: A process performed on a server includes configuring the server to enable script for a Web service to be defined dynamically, where the Web service includes an application program interface (API) for enabling access by, and interaction with, a computer program executing on a device other than the server. The process also includes compiling the script to produce machine-executable code for the Web service, receiving a call from the computer program to the Web service, executing the machine-executable code in response to the call to produce an output, and sending the output to the device.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: February 25, 2020
    Assignee: PTC Inc.
    Inventor: Joseph L. Biron, III
  • Processing uncertain content in a computer graphics system
    Patent number: 10572716
    Abstract: An example method includes: obtaining, from computer memory, information from a three-dimensional (3D) graphical model that represents an object; identifying, based on the information, a first part of the object having an attribute; performing a recognition process on the object based on features of the object, where the recognition process attaches more importance to a second part of the object than to the first part, with the second part either not having the attribute or having less of the attribute than the first part; and providing data for rendering content on a graphical user interface based, at least in part, on recognition of the object performed by the recognition process.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 25, 2020
    Assignee: PTC Inc.
    Inventors: Stephen Prideaux-Ghee, Andre Gosselin, Per Nielsen, Vincent Del Castillo, Qi Pan, Michael Gervautz
  • Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease
    Patent number: 10555960
    Abstract: Methods of using and pharmaceutical compositions comprising (2R,3S,4R,5R,6S)-5-amino-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-2-hydroxycyclohexyl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol are disclosed, including methods of treating or preventing a nonsense mutation mediated disease associated with premature translation termination or a premature stop codon resulting from a germline or somatic nonsense mutation.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 11, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventor: Ramil Y. Baiazitov
  • Methods for treating epilepsy
    Patent number: 10517853
    Abstract: Provided herein are methods of treating, preventing, ameliorating or managing a nonsense mutation mediated epileptic disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nonsense mutation mediated epileptic disease. In particular, provided herein are methods of treating, preventing, ameliorating or managing a CDKL5 and/or SCN1A (Dravet syndrome) nonsense mutation mediated epileptic disease.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 31, 2019
    Assignee: PTC Therapeutics, Inc.
    Inventors: Ellen Welch, Yuki Tomizawa, Priya Vazirani
  • Compounds for treating spinal muscular atrophy
    Patent number: 10501482
    Abstract: The present invention provides compounds of formula (I) wherein A, B, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: December 10, 2019
    Assignees: Hoffmann—La Roche Inc., PTC Therapeutics Inc.
    Inventors: Amal Dakka, Luke Green, Gary Karp, Jana Narasimhan, Nikolai Naryshkin, Emmanuel Pinard, Hongyan Qi, Hasane Ratni, Nicole Risher, Marla Weetall, Matthew Woll
  • METHODS FOR MODULATING RNA SPLICING
    Publication number: 20190330615
    Abstract: In one aspect, described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a compound provided herein. In another aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains an intronic REMS, and the methods utilizing a compound described herein. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product encoded by a gene, wherein a precursor RNA transcript transcribed from the gene comprises an intronic REMS, and the methods utilizing a compound described herein. In another aspect, provided herein are artificial gene constructs comprising an intronic REMS, and uses of those artificial gene constructs to modulate protein production.
    Type: Application
    Filed: November 27, 2017
    Publication date: October 31, 2019
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Anuradha Bhattacharyya, Amal Dakka, Kerstin Effenberger, Vijayalakshmi Gabbeta, Wencheng Li, Nikolai Naryshkin, Christopher Trotta, Kari Wiedinger
  • COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
    Publication number: 20190315773
    Abstract: The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 17, 2019
    Applicants: Hoffmann-La Roche Inc., PTC Therapeutics, Inc.
    Inventors: Hasane Ratni, Luke Green, Maria L. Weetall, Nikolai A. Naryshkin
  • Micronized colistimethane sodium pharmaceutical compositions
    Patent number: 10441536
    Abstract: Described herein are micronized powder particles of colistimethate sodium wherein at least 50% by volume of the micronized particles have a diameter of less than 7 micrometers but not less than 3 micrometers and the powder has a total moisture content of from 5 to 10% by weight, for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistimethate sodium is not separated into component form. The micronized powder particles of colistimethate sodium are useful in the treatment of infections caused by gram-negative bacteria, particularly in patients suffering from cystic fibrosis.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: October 15, 2019
    Assignee: ACTAVIS GROUP PTC EHF
    Inventors: Richard Anthony Flynn, Rahul Surana, Anil Chhettry, David Farrington, Ritesh Sanghvi
  • System and method of injecting states into message routing in a distributed computing environment
    Patent number: 10432712
    Abstract: A system and method of operating resources within a distributed computing environment. The resources include a platform server and intermediate servers where each of the intermediate servers connects and maintains a persistent connection to the platform server a number of edge servers. The method includes injecting state identifier information into service requests from a given edge server to the intermediate server and transmitting the service request to the platform server. The method includes receiving to response message from the platform server where the message includes the state identifier. The method includes using the state identifier to route the message to the given edge server.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: October 1, 2019
    Assignee: PTC Inc.
    Inventors: Mike Mahoney, Bob DeRemer, Rick Bullotta
  • Substituted reverse pyrimidine Bmi-1 inhibitors
    Patent number: 10428050
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: October 1, 2019
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W Davis, Wu Du, Ronggang Liu, Young-choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Augmented reality system
    Patent number: 10431005
    Abstract: An example augmented reality system includes: obtaining information about an instance of a device; recognizing the instance of the device based on the information; selecting a digital twin for the instance of the device, with the digital twin being unique to the instance of the device; and generating augmented reality content based on the digital twin and an actual graphic of the instance of the device.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 1, 2019
    Assignee: PTC Inc.
    Inventors: Vladimir Parfenov, Kevin Elliott Jordan, Steven Thomas Dertien, Moshe Jacob Baum, Andre Gosselin, Stephen Prideaux-Ghee, James E. Heppelman
  • Adaptive device-initiated polling
    Patent number: 10425317
    Abstract: A method includes periodically sending a polling call to an enterprise system outside the firewall at a first polling rate during normal operating conditions, monitoring for a fault condition, periodically sending polling calls to the device outside the firewall at a second polling rate when a fault condition is detected, the second polling rate being higher than the first polling rate. The second polling rate is used as result of a fault condition. The method also includes sending a problem report with the polling calls when the fault condition is detected.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: September 24, 2019
    Assignee: PTC Inc.
    Inventors: John Louis Taylor, John Thomas Canosa
  • Compounds for treating spinal muscular atrophy
    Patent number: RE47689
    Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: November 5, 2019
    Assignees: PTC Therapeutics, Inc., F. Hoffmann-La Roche
    Inventors: Matthew G. Woll, Guangming Chen, Soongyu Choi, Amal Dakka, Song Huang, Gary Mitchell Karp, Chang-Sun Lee, Chunshi Li, Jana Narasimhan, Nikolai Naryshkin, Sergey Paushkin, Hongyan Qi, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Emmanuel Pinard, Hasane Ratni